| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | CVRx Reports Q2 2026 Results: Full Earnings Call Transcript | 2 | Benzinga.com | ||
| 29.09. | CVRx, Inc.: CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026 | 3 | GlobeNewswire (USA) | ||
| 23.09. | CVRx Appoints John Landry As CFO To Support Barostim Commercial Expansion | 1 | pulse2.com | ||
| 22.09. | CVRx taps new CFO from Nyxoah | 2 | MassDevice | ||
| 22.09. | Canaccord reiterates CVRx stock Buy rating after CFO appointment | 1 | Investing.com | ||
| 21.09. | CVRx Appoints As John Landry CFO | 5 | RTTNews | ||
| CVRX Aktie jetzt für 0€ handeln | |||||
| 21.09. | CVRx appoints medical device veteran John Landry as new CFO | 5 | Seeking Alpha | ||
| 21.09. | CVRx appoints John Landry as chief financial officer | 5 | Investing.com | ||
| 21.09. | CVRx, Inc.: CVRx Appoints John Landry as Chief Financial Officer | 203 | GlobeNewswire (Europe) | MINNEAPOLIS, Sept. 21, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation... ► Artikel lesen | |
| 17.09. | CVRx informiert zum Weltherztag am 29. September / Bluthochdruck: Den wichtigsten Risikofaktor für Herz-Kreislauf-Erkrankungen früh erkennen und behandeln | 399 | news aktuell | Minneapolis (ots) - Herz-Kreislauf-Erkrankungen sind die häufigste Todesursache in Deutschland und weltweit. Viele Risikofaktoren wie Bluthochdruck, erhöhte Cholesterinwerte oder Diabetes entwickeln... ► Artikel lesen | |
| 25.08. | CVRx has an activist investor urging it to get acquired | 3 | MassDevice | ||
| 25.08. | CVRx responds to shareholder letter on company valuation | 2 | Investing.com | ||
| 24.08. | CVRx earns new Medicare Advantage coverage policy for Barostim | 1 | MassDevice | ||
| 24.08. | CVRx, Inc.: CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy | 1 | GlobeNewswire (USA) | ||
| 17.08. | Cantor cuts CVRx stock price target on sales execution challenges | 1 | Investing.com | ||
| 11.08. | CVRx auf der Canaccord Genuity Wachstumskonferenz: Fortschritte bei Kostenerstattung, aber Belastungen im Vertrieb | 1 | Investing.com Deutsch | ||
| 11.08. | CVRx to replace CRO after cutting guidance and DOJ civil inquiry | 1 | MassDevice | ||
| 11.08. | CVRx, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.08. | CVRx forecasts 2026 revenue of $58M-$60M amid sales productivity and medicare advantage headwinds | 1 | Seeking Alpha | ||
| 07.08. | Piper Sandler stuft CVRx-Aktie wegen Vertriebs- und Kostenerstattungsproblemen herab | 1 | Investing.com Deutsch |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 5,350 | +0,72 % | Teladoc Health Adds Contactless Vitals and Ambient AI Scribe to Virtual Visit Platform | ||
| SERNOVA BIOTHERAPEUTICS | 0,063 | -5,09 % | Sernova Biotherapeutics Inc ÜBERRASCHT Anleger: Meine brandneue Prognose ändert einfach alles - Dringend vor Börsenschluss handeln! | ||
| CERENOME | 1,616 | +7,45 % | Cerenome, Inc.: Cerenome Launches CNSide CSF Molecular Profile Tests | HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), today announced the commercial launch... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 2,160 | +0,93 % | Atossa Therapeutics schließt CVR-Vereinbarung für Erlöse aus FDA-Prüfgutschein | ||
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals, Inc. - 8-A12B/A, Registration of securities | ||
| TANDEM DIABETES | 14,800 | 0,00 % | Tandem Diabetes Care Q2 2026 Earnings Call Transcript | ||
| CO-DIAGNOSTICS | 1,250 | 0,00 % | Co-Diagnostics Reports Second Quarter 2026 Financial Results | Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion
Strengthening Integrated Co-Dx PCR Platform Through Scientific... ► Artikel lesen | |
| QUIDELORTHO | 12,000 | +1,14 % | Sanjeev Sharma wird neuer Leiter Investor Relations bei QuidelOrtho | ||
| VERU | 2,415 | +0,42 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -5- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS75973T2006 RENALYTIX... ► Artikel lesen | |
| LIFEWARD | 6,360 | +1,92 % | Lifeward Ltd. - 8-K, Current Report | ||
| CLOVER HEALTH INVESTMENTS | 4,370 | +2,10 % | Why Is Clover Health (CLOV) Stock Soaring Today | ||
| SENSEONICS | 8,300 | 0,00 % | Senseonics Holdings Q2 2026 Earnings Call: Complete Transcript | ||
| TEMPEST THERAPEUTICS | 0,740 | -0,35 % | Tempest Therapeutics beruft Nancy Freda-Smith in den Verwaltungsrat | ||
| NANO-X IMAGING | 0,508 | -0,39 % | Nano-X Imaging Ltd: Nanox Expands Latin American Presence with Nanox.ARC Distribution Agreement in Costa Rica | Agreement with SOLME RC, SA Marks the third Latin American market this year PETACH TIKVA, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd. (NASDAQ: NNOX) ("Nanox"), a leader in innovative... ► Artikel lesen | |
| IMUNON | 0,950 | -0,52 % | Imunon, Inc.: IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer | Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company's large, randomized Phase II study, OVATION... ► Artikel lesen |